Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03417869 · ClinicalTrials.gov registry record
QuickVue Influenza A + B Test Field Study
A clinical trial, sponsored by Quidel Corporation.
- Completed
- Registry status
- 1,381
- Enrollment target
NCT03417869: Completed study, sponsored by Quidel Corporation.
NCT03417869 is a clinical trial that has completed, run by Quidel Corporation. The registered enrollment target is 1,381 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03417869 has completed, sponsored by Quidel Corporation.
- COMPLETED
- Registry status
- 1,381 participants
- Enrollment target
Study Summary
Demonstrate improved clinical performance of visually read QuickVue Influenza A+B test.
Primary Outcome
rapid IVD test
Interventions
- DEVICE QuickVue Influenza A+B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,381 participants |
| Start Date | 2017-02-16 |
| Est. Completion | 2018-02-01 |
What the finished NCT03417869 record still lists
NCT03417869 is an observational study that tracks outcomes without assigning an intervention. Its 1,381 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which QuickVue Influenza A+B is the first listed.
NCT03417869 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03417869 about?
NCT03417869 is a clinical study titled "QuickVue Influenza A + B Test Field Study". Demonstrate improved clinical performance of visually read QuickVue Influenza A+B test.
What is the current status of trial NCT03417869?
This trial is currently completed. The enrollment target is 1,381 participants. The study started on 2017-02-16. Estimated completion is 2018-02-01.
What interventions are being tested in trial NCT03417869?
The interventions under investigation include: QuickVue Influenza A+B (DEVICE).
Who is sponsoring clinical trial NCT03417869?
This trial is sponsored by Quidel Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06651281 · 1,380 participants · Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT05006131 · 1,395 participants
Pancreatic Cancer Screening for At-risk Individuals
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI